This trial will compare apixaban with aspirin to see which reduces the risk of stroke better in patients with atrial fibrillation and other stroke risk factors.
2 Primary · 6 Secondary · Reporting Duration: event driven, duration of follow-up - mean follow-up time anticipated: 3 years
4012 Total Participants · 2 Treatment Groups
Primary Treatment: Apixaban · No Placebo Group · Phase 4
Age 18+ · All Participants · 9 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|Cardiovascular Associates of Marin and San Francisco Medical||100.0%|
|Did not meet criteria||100.0%|